Table 3.
Immune protection afforded by traditional vaccines against P. multocida serogroup D strains.
| Experiment | Immunization Group | Immune Dose (µL) | Challenge Strain | Challenge Dose (CFU) | No. of Mice | No. of Mice Survived | Protective Efficacy |
|---|---|---|---|---|---|---|---|
| Experiment 4 | Alh-C44-1 inactivated vaccines | 200 | PM-15 | 8 LD50 | 7 | 2 | 29% |
| EO630 live vaccine | 200 | PM-15 | 8 LD50 | 7 | 2 | 29% | |
| Control | 200 | PM-15 | 8 LD50 | 7 | 1 | 14% | |
| Experiment 5 | Alh-C44-1 inactivated vaccine | 200 | PM-15 | 10 LD50 | 5 | 1 | 20% |
| EO630 live vaccine | 200 | PM-15 | 10 LD50 | 5 | 1 | 20% | |
| Control | 200 | PM-15 | 10 LD50 | 5 | 0 | 0 | |
| Experiment 6 | Alh-C44-1 inactivated vaccine | 200 | PM-G1 | 25 LD50 | 5 | 1 | 20% |
| EO630 live vaccine | 200 | PM-G1 | 25 LD50 | 5 | 1 | 20% | |
| Control | 200 | PM-G1 | 25 LD50 | 5 | 0 | 0 |